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Abstract
Chronic obstructive pulmonary disease (COPD) is associated with a high disease burden and is one of the leading 
causes of death worldwide. Smoking is the key modifiable risk factor for COPD in Germany. GEDA 2014/2015-EHIS 
surveyed the 12-month prevalence of known COPD using the European indicator on self-reported chronic bronchitis, 
chronic obstructive pulmonary disease, emphysema. Among adults aged 18 years or older with complete information 
on the indicator (n=22,702), the 12-month prevalence of known COPD is 5.8% (5.8% for women and 5.7% for men). 
In both genders, the prevalence increases strongly with age. Overall, the presence of COPD was more often reported 
by women and men with a low educational level than by those with a higher one. In a comparison of federal states, 
the 12-month prevalence of known COPD varies between 3.6% and 7.5% for women and 4.3% and 11.2% for men.
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Introduction
Chronic obstructive pulmonary disease (COPD) is asso-
ciated with a high disease burden and is one of the lead-
ing causes of death in Germany and globally [1-3]. COPD 
is a prevalent chronic disease of middle and older age 
[1, 4-7]. It is marked by chronic inflammation and pro-
gressive obstruction (narrowing) of the airways and 
destruction of lung tissue (parenchyma) [1, 8]. Chronic 
cough and phlegm production (chronic bronchitis) as 
well as a permanent over-inflation of the air sacks 
(emphysema) are common among COPD patients and 
often occur together [1, 8]. Moreover, shortness of breath 
under physical strain is a typical symptom. At more pro-
gressed stages of the disease, patients may also suffer 
from shortness of breath even at rest [1, 8].
Smoking is the most important modifiable risk fac-
tor for COPD in Germany [1, 7-9]. The risk of develop-
ing COPD is thereby related to the total amount of 
cigarette smoking over time (pack years) [7, 9]. More-
over, specific occupational exposures (e.g., coal dust) 
are important COPD risk factors [1, 7, 9, 10]. COPD is 
therefore considered a potentially preventable disease 
[1, 8]. However, impaired growth and functional devel-
opment of the lungs also affect a person’s COPD risk 
[1, 9, 11]. Besides genetic factors and prenatal influ-
ences (e.g., maternal smoking during pregnancy), 
repeated respiratory infections in early childhood, 
exposure to airborne pollutants, or childhood asthma 
potentially contribute to developing COPD in later life 
[1, 7, 9, 12, 13].
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December 2014) with regard to gender, age, district type 
and education. The district type reflects the degree of 
urbanisation and corresponds to the regional distribu-
tion in Germany. The International Standard Classifica-
tion of Education (ISCED) was used to classify the 
responses provided on educational level [19]. Lange et 
al. [20] set out the details of the methodology applied 
in GEDA 2014/15-EHIS including a description of the 
method used to calculate the weighting factor and an 
assessment of the response rate. Background informa-
tion on GEDA 2014/15-EHIS are also provided in the 
article German Health Update: New data for Germany 
and Europe, which was published in Issue 1/2017 of the 
Journal of Health Monitoring.
Results and discussion 
In GEDA 2014/2015-EHIS, 5.8% of adults aged 18 years 
or older reported the presence of COPD during the past 
12 months. The 12-month prevalence of known COPD 
for women (5.8%) is comparable to the prevalence for 
men (5.7%). In both genders, the 12-month prevalence 
increases strongly with age (Table 1). Overall, the pres-
ence of COPD was more often reported by women and 
men with a low educational level than by those with a 
medium or high one (8.1% vs. 5.7% and 4.0%). Strati-
fied by age and sex, these differences with regard to edu-
cational level are particularly evident for women under 
65 years of age and for men aged 45 to 64 years (Table 
1). The prevalence of known COPD varies considerably 
between federal states, ranging from 3.6% in Saxony-An-
halt to 7.5% in Bremen for women and from 4.3% in 
Hesse to 11.2% in Saarland for men (Figure 1).
Adults with COPD frequently suffer from other 
chronic conditions such as cardiovascular diseases [1, 
7, 9]. These concurrent conditions considerably impact 
the quality of life of COPD patients and contribute to 
the high COPD-related costs of illness [14-17]. COPD-re-
lated costs of illness are also significantly determined 
by the severity of the disease [17, 18]. A recent study of 
COPD patients in Germany revealed that in compari-
son to a control group from the region of Augsburg, 
excess (direct) costs resulting from healthcare utiliza-
tion ranged between 2,595 and 8,924 EUR per patient 
in 2012 [17].  The indirect costs (e.g., due to work 
absence) were significantly higher ranging from 8,621 
to 27,658 EUR [17].
Indicator 
GEDA 2014/2015-EHIS surveyed the prevalence of 
known COPD during the past 12 months based on an 
instrument from the indicator set of the European health 
monitoring by using self-administered paper-based or 
online questionnaires. Respondents were asked, 'Dur-
ing the past 12 months, have you had any of the follow-
ing diseases or conditions?' This question was followed 
by a list of conditions that also included 'chronic bron-
chitis, chronic obstructive pulmonary disease, emphy-
sema’. Out of a total of 24,016 respondents aged 18 
years or older (13,144 women, 10,872 men), 1,314 
respondents (696 women and 618 men) with missing 
information on the indicator were excluded from the 
analysis. COPD prevalence was calculated using a 
weighting factor that corrects for deviations within the 
sample from the German population structure (as of 31 
GEDA 2014/2015-EHIS
Data holder: Robert Koch Institute
Aims: To provide reliable informa tion 
about the population’s health status, 
health-related behaviour and health care  
in Germany, with the possibility of a  
European comparison 
Method: Questionnaires completed on 
paper or online
Population: People aged 18 years and above 
with permanent residency in Germany
Sampling: Registry office sample; randomly 
selected individuals from 301 communities 
in Germany were invited to participate
Participants: 24,016 people (13,144 women; 
10,872 men)
Response rate: 26.9%
Study period: November 2014 - July 2015
Data protection: This study was undertaken 
in strict accordance with the data protection 
regulations set out in the German Federal 
Data Protection Act and was approved by 
the German Federal Commissioner for Data 
Protection and Freedom of Information.  
Participation in the study was voluntary. 
The participants were fully informed about 
the study’s aims and content, and about 
data protection. All participants provided 
written informed consent.
 
More information in German is available at 
www.geda-studie.de
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Prevalence estimates for this indicator were 6.0% for 
women and 4.0% for men [21].
Besides interview data, COPD prevalence estimates 
are mainly based on data obtained from a pulmonary 
function test (spirometry) [4, 6, 18, 22, 23]. However, 
there is poor agreement between estimates of spiromet-
rically defined and self-reported COPD prevalence [4, 6, 
22, 24, 25]. For example in a population-based cohort 
study among adults 41 to 90 years of age from the region 
of Augsburg (KORA), less than 40% of participants with 
spirometrically defined COPD reported to have physi-
cian-diagnosed COPD [22]. This was explained by a high 
When comparing these results on the prevalence of 
known COPD with the results from previous epidemio-
logical studies, considerable methodological differences 
need to be taken into account. For example, a compari-
son with the results from the interview survey of adults 
aged 18 years or older conducted by the Robert Koch 
Institute in 2012 (GEDA 2012) is not possible because 
both the type of the interview (written/online question-
naire now, telephone interview then) and the indicator 
differ [21]. GEDA 2012 surveyed the 12-month prevalence 
of physician-diagnosed chronic bronchitis defined as 
coughing with phlegm for at least 3 months per year [21]. 
Women % (95% CI)
Women total 5.8 (5.2-6.4)
18-29 Years 2.4 (1.6-3.5)
Low education 4.5 (2.5-8.2)
Medium education 2.0 (1.2-3.3)
High education 0.7 (0.3-1.9)
30-44 Years 3.4 (2.7-4.4)
Low education 7.4 (4.5-11.9)
Medium education 2.9 (2.0-4.1)
High education 2.5 (1.5-4.0)
45-64 Years 5.1 (4.3-5.9)
Low education 7.2 (5.2-9.8)
Medium education 5.1 (4.2-6.2)
High education 3.3 (2.4-4.5)
≥ 65 Years 11.0 (9.5-12.7)
Low education 10.8 (8.6-13.5)
Medium education 11.2 (9.2-13.6)
High education 9.4 (6.1-14.0)
Total (women and men) 5.8 (5.4-6.2)
CI=Confidence interval
Men % (95% CI)
Men total 5.7 (5.2-6.3)
18-29 Years 1.3 (0.8-2.3)
Low education 2.0 (0.7-5.3)
Medium education 1.2 (0.6-2.4)
High education 0.7 (0.3-1.8)
30-44 Years 2.0 (1.4-2.9)
Low education 2.8 (1.2-6.2)
Medium education 2.5 (1.7-3.9)
High education 0.9 (0.4-1.9)
45-64 Years 6.3 (5.4-7.4)
Low education 12.1 (8.8-16.3)
Medium education 7.0 (5.8-8.5)
High education 3.1 (2.4-4.1)
≥ 65 Years 12.5 (10.9-14.3)
Low education 15.5 (11.7-20.1)
Medium education 12.2 (10.0-14.8)
High education 11.6 (9.4-14.3)
Total (women and men) 5.8 (5.4-6.2)
Table 1 
12-month prevalence of known COPD accor-
ding to gender, age and educational level 
(n=12,448 women; n=10,254 men) 
Source: GEDA 2014/2015-EHIS
* n=50 additional missing values (25 women and men) when stratifying by educational level
The 12-month prevalence of 
known COPD is 5.8% for 
women and 5.7% for men.
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take into account that lung function generally decreases 
with age and also shows  considerable variation in the 
older population [27-29]. In particular, age-specific esti-
mates on COPD prevalence based on spirometry data 
differ depending on the chosen reference criteria and 
method of examination, e.g. with or without the use of 
medications to dilate airways [1, 9, 22, 27-29]. Besides, 
number of undiagnosed COPD cases [22], a fact that 
results in an underestimation of the actual COPD preva- 
lence when using self-reported information [1, 9, 25, 26]. 
In line with other studies, GEDA 2014/2015-EHIS sur-
vey data also demonstrate that COPD is an age-associ-
ated disease [1, 4-7]. A comparison with prevalence esti-
mates of spirometrically defined COPD must, however, 








































12-month prevalence of known COPD accor-
ding to gender and federal state 
(n=12,448 women; n=10,254 men) 
Source: GEDA 2014/2015-EHIS
Confidence intervals in parentheses
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COPD was based on the composite indicator compel-
ling information on chronic bronchitis, chronic obstruc-
tive pulmonary disease, emphysema in line with other 
cross-country surveys [4, 6, 23]. Thereby, however, adults 
with chronic cough and phlegm production might have 
been included who have otherwise normal spirometry 
results and will not develop COPD in later life [1, 32-34]. 
This is particularly relevant with regard to the prevalence 
of known COPD assessed among young adults in GEDA 
2014/2015-EHIS [31]. Moreover, current findings on the 
prevalence of known COPD are based on the self-assess-
ment of respondents and not on self-reported medical 
diagnoses [4, 6, 22, 24]. This increases the likelihood of 
misclassifying patients with other diseases that are 
marked by similar symptoms, in particular asthma [31].
In accordance with other data on spirometrically 
defined COPD, GEDA 2014/2015-EHIS results indicate 
a higher prevalence of known COPD among adults with 
a low educational level compared to those with a higher 
one [7, 9, 35, 36]. In line with these findings, comparable 
differences in prevalence had previously been reported 
with regard to different socio-economic criteria [7, 9, 35, 
36]. GEDA 2014/2015-EHIS revealed considerable 
regional differences in the prevalence of known COPD 
not only between federal states but also between EU 
countries. Germany thereby ranked in the group of coun-
tries presenting the highest prevalence [37] (see issue 
1/2017 Journal of Health Monitoring). The interpretation 
of social and regional differences in known COPD preva- 
lence needs to consider differences in the distribution 
of risk factors such as smoking (see also the Fact sheet 
Smoking among adults in Germany in issue 2/2017 Jour-
the available prevalence data on spirometrically defined 
COPD is based alone on the detection of an airflow 
obstruction [1, 4, 6]. A clinical diagnosis of COPD, how-
ever, also requires the consideration of risk factors, 
symptoms, the corresponding individual clinical history 
and, where necessary, further clinical examinations [1, 9, 
27, 29]. 
Results from international surveys including data 
from Germany reveal a higher prevalence of spirometri-
cally defined COPD among men than among women [5, 
7, 18, 24, 30, 31]. For example, the estimated prevalence 
of spirometrically defined COPD among adults 40 year 
of age or older was 9.3% for women and 18.1% for men 
based on data collected in the German study centre 
Hanover of the international Burden of Obstructive Lung 
Disease (BOLD) study in 2006  [24]. This difference 
between women and men was observed independent of 
disease severity [5]. Higher prevalence among men, how-
ever, was only seen among those aged 50 years or older 
and was considered to be potentially related to the gen-
der-specific differences in smoking habits across age 
groups [24]. In agreement with the findings presented 
here, results from this previous survey demonstrated 
that there were no gender differences regarding the preva- 
lence of a known COPD: 7.7% of women and 7.6% of 
men reported to have been diagnosed with COPD by a 
physician [24]. Further analyses on the basis of BOLD 
and other survey data indicated underlying differences 
in COPD awareness between women and men, as male 
gender was associated with an undiagnosed COPD [25]. 
In the GEDA 2014/2015-EHIS survey conducted across 
Europe, data collection on the prevalence of known 
The presence of COPD was 
more often reported by 
women and men with a low 
educational level than by 
those with a higher one.
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nal of Health Monitoring) as well as in COPD awareness 
and care provision [36, 38-40]. Periodically repeated col-
lection of nationally representative population-based 
data on major modifiable risk factors as well as on lung 
function, diagnosis, symptoms, and mortality of COPD 
is essential in order to identify successes and remaining 
or new challenges of COPD prevention and care. 
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